All In Biotech

Drug Trial Radar · NCT07215702

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Feb 11, 2027

Study completion Feb 11, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.

Conditions

  • Sepsis
  • Acute Kidney Injury

Interventions

  • AZD4144Drug

    Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned.

  • PlaceboDrug

    Intravenous solution of Placebo will be administered to randomised participants according to the treatment arm to which they have been assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl).Time frame: During the treatment period.

Locations

74 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Newport Beach, California · Recruiting

  • Research Site

    Kansas City, Kansas · Recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    The Bronx, New York · Recruiting

  • Research Site

    The Bronx, New York · Recruiting

  • Research Site

    The Bronx, New York · Recruiting

  • Research Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Research Site

    Winston-Salem, North Carolina · Recruiting

  • Research Site

    Corvallis, Oregon · Withdrawn

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Research Site

    Charleston, South Carolina · Recruiting

  • Research Site

    Salt Lake City, Utah · Withdrawn

  • Research Site

    CABA, Argentina · Withdrawn

  • Research Site

    Ciudad de Buenos Aires, Argentina · Recruiting

  • Research Site

    La Plata, Argentina · Recruiting

  • Research Site

    Rosario, Argentina · Recruiting

  • Research Site

    Brussels, Belgium · Recruiting

  • Research Site

    Genk, Belgium · Recruiting

  • Research Site

    Jette, Belgium · Recruiting

  • Research Site

    Ottignies, Belgium · Recruiting

  • Research Site

    Lévis, Quebec, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Withdrawn

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Québec, Quebec, Canada · Recruiting

  • Research Site

    Québec, Quebec, Canada · Not yet recruiting

  • Research Site

    Brno, Czechia · Not yet recruiting

  • Research Site

    Kolín, Czechia · Recruiting

  • Research Site

    Prague, Czechia · Withdrawn

  • Research Site

    Prague, Czechia · Recruiting

  • Research Site

    Aarhus N, Denmark · Withdrawn

  • Research Site

    Gistrup, Denmark · Recruiting

  • Research Site

    Hvidovre, Denmark · Recruiting

  • Research Site

    Angers, France · Withdrawn

  • Research Site

    Brive-la-Gaillarde, France · Not yet recruiting

  • Research Site

    La Roche-sur-Yon, France · Recruiting

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.